Abstract
The most common bone disorder found by implant dentists is osteoporosis, a systemic skeletal disorder associated with aging characterized by loss of bone mass, making bones fragile and more susceptible to fractures. The World Health Organisation has defined osteoporosis as a bone mineral density level greater than 2.5 standard deviations below the mean of young normal women. After 60 years of age, a third of the population has this disorder; it occurs twice as often in women as in men. It is estimated that 1.3 million fractures and 133,000 hip fractures occur every year as a result of osteoporosis. The aim of this study was to discuss aspects of the pharmacological action of Bisphosphonates (BP) and their influence on bone tissue when associated with treatment with dental implants. The PRISMA rules were followed. The search was conducted from February to April 2026 across the PubMed, Scopus, Web of Science, Embase, Cochrane, Ovid, Periodicos.com, Harvard Library, and Google Scholar. 64 articles were found, 35 articles were evaluated in full, and 26 were included and developed in the present systematic review study. There are several types of treatments that prevent or prevent the progression of osteoporosis. So, BP, such as alendronate, are inhibitors of bone resorption. Act as controlling the development of osteoporosis by increasing the process of bone density and decreasing its reabsorption, often supporting the process of osseointegration of dental implants.